Agios Secures EU Approval for PYRUKYND® (mitapivat) to Treat Adults Living with Thalassaemia, Announces Avanzanite Bioscience
Avanzanite Bioscience B.V. has announced a major milestone in the treatment of rare blood disorders following the European Commission’s approval of PYRUKYND® (mitapivat) for adults living with alpha- or beta-thalassaemia associated with anaemia. The approval marks an important advancement for patients across Europe and strengthens the growing role of targeted therapies in the management of rare hematologic diseases.
The decision by the European Commission grants marketing authorisation for PYRUKYND, an oral pyruvate kinase (PK) activator developed by Agios Pharmaceuticals, for use in both transfusion-dependent and non-transfusion-dependent thalassaemia patients. The therapy also received orphan medicinal product designation, reflecting the significant unmet medical need within this rare disease population.
The approval follows positive recommendations from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and is based on encouraging data from the global Phase 3 ENERGIZE and ENERGIZE-T clinical trials. These studies demonstrated the therapy’s potential to improve anaemia and reduce transfusion burden in adults living with thalassaemia.
Thalassaemia is an inherited blood disorder that affects hemoglobin production, leading to chronic anaemia, ineffective red blood cell production, and hemolysis. The disease can place a lifelong burden on patients, often requiring frequent blood transfusions, iron chelation therapy, and ongoing medical management. Patients commonly experience fatigue, weakness, organ complications, and reduced quality of life.
Experts in the field welcomed the approval as a meaningful step forward for the thalassaemia community. Raffaella Origa, M.D., Ph.D., Professor of Paediatrics at the University of Cagliari in Italy and President of the Italian Society of Thalassaemia and Haemoglobinopathies, said the condition remains a complex and chronic disease that significantly impacts patients physically and emotionally.
According to Origa, PYRUKYND introduces an important new oral treatment option capable of addressing key aspects of the disease regardless of genotype or transfusion burden. She noted that the therapy may help reduce transfusion needs while improving overall patient outcomes and quality of life.
The approval is especially notable because it covers both transfusion-dependent and non-transfusion-dependent forms of alpha- and beta-thalassaemia. Historically, treatment options for these patient groups have been limited, and many therapies are focused primarily on symptom management rather than targeting underlying disease mechanisms.
PYRUKYND works by activating pyruvate kinase, an enzyme involved in red blood cell metabolism. By improving energy production within red blood cells, the therapy aims to enhance red blood cell function and survival, potentially reducing anaemia and the need for repeated transfusions.
The medicine previously received approval in the European Union in 2022 for adults with pyruvate kinase deficiency, another rare inherited blood disorder. The latest authorisation expands its reach into the broader thalassaemia population and highlights the growing clinical potential of pyruvate kinase activation as a therapeutic strategy.
Clinical investigators involved in the Phase 3 studies emphasized the significance of introducing an oral treatment option into thalassaemia care. Antonis Kattamis, M.D., Professor at the National and Kapodistrian University of Athens and an investigator in the PYRUKYND thalassaemia program, said current treatment approaches continue to place a heavy burden on both patients and healthcare systems.
He explained that frequent transfusions, hospital visits, and long-term supportive therapies can create significant physical, emotional, and financial strain for patients and families. Kattamis noted that an oral therapy such as PYRUKYND has the potential to transform disease management for both transfusion-dependent and non-transfusion-dependent patients.
The approval also represents a major commercial milestone for Avanzanite Bioscience. In June 2025, the company entered into an exclusive agreement with Agios Pharmaceuticals to commercialise and distribute PYRUKYND throughout the European Economic Area, the United Kingdom, and Switzerland.
Under the agreement, Avanzanite will oversee regional commercial operations and collaborate with healthcare authorities, physicians, and patient advocacy groups to expand patient access to the therapy across Europe. The company plans to work closely with Agios to support launch activities, reimbursement discussions, and broader market access initiatives.
Adam Plich, CEO and Co-Founder of Avanzanite Bioscience, described the approval as highly significant for adults living with thalassaemia throughout Europe. He said the company is proud to partner with Agios in bringing the first-in-class PK activator to patients who may benefit from an alternative to traditional treatment approaches.
According to Plich, Avanzanite’s immediate focus will be on ensuring successful launches across European markets while working with local healthcare systems to provide broad access to the therapy. He emphasized the company’s goal of helping ensure that no thalassaemia patient across Europe is left behind.
The latest approval further strengthens Avanzanite’s growing reputation within the rare disease sector. The company has rapidly expanded its commercial infrastructure in recent years and has now led four rare disease launches across Europe.
Avanzanite currently operates in 32 European countries with a team of more than 100 rare disease professionals. The company has positioned itself as a specialized commercial partner for biotechnology innovators seeking to bring advanced therapies to European patients with rare conditions.
The PYRUKYND launch also highlights increasing momentum within the rare hematology treatment landscape. Advances in targeted therapies, gene therapies, and novel disease-modifying medicines are beginning to reshape treatment expectations for disorders such as thalassaemia, sickle cell disease, and pyruvate kinase deficiency.
For decades, many patients with thalassaemia have depended heavily on regular blood transfusions to manage chronic anaemia. While transfusions can help maintain hemoglobin levels, they are associated with significant long-term complications, including iron overload, organ damage, and increased healthcare utilisation.
Non-transfusion-dependent patients may also experience serious complications despite requiring fewer transfusions. Chronic anaemia can contribute to fatigue, bone abnormalities, cardiovascular issues, and impaired daily functioning, creating substantial quality-of-life challenges.
The development of oral therapies like PYRUKYND could therefore provide important new options for patients seeking alternatives to traditional supportive care. Physicians hope that treatments targeting the underlying biology of the disease may eventually reduce dependence on transfusions and improve long-term health outcomes.
The ENERGIZE and ENERGIZE-T Phase 3 studies played a central role in supporting the European Commission’s decision. The trials were randomised, double-blind, and placebo-controlled, designed to rigorously evaluate both efficacy and safety across diverse thalassaemia patient populations.
Results from the studies demonstrated clinically meaningful improvements in anemia-related measures while supporting the overall safety and tolerability profile of the therapy. Investigators believe these findings support the role of PYRUKYND as a potential new standard treatment option for adults with thalassaemia.
The orphan medicinal product designation granted alongside the approval reflects the European Union’s support for therapies addressing rare diseases with limited treatment options. Orphan designation is intended to encourage the development of innovative therapies for conditions affecting small patient populations.
Industry analysts view the approval as another important validation of Agios Pharmaceuticals’ rare disease strategy. The company has increasingly focused on developing therapies that target cellular metabolism and genetically defined disorders.
For Avanzanite, the partnership with Agios further expands its commercial portfolio and demonstrates its ability to support the launch of innovative rare disease medicines across multiple European markets. The company’s pan-European infrastructure may help accelerate access to therapies that might otherwise face delayed adoption due to fragmented healthcare systems and reimbursement challenges.
Patient organisations are also expected to play an important role in supporting awareness and access efforts as PYRUKYND becomes available across Europe. Advocacy groups have long emphasised the need for more treatment options capable of reducing the burden of chronic transfusions and improving day-to-day quality of life for thalassaemia patients.
The approval of PYRUKYND represents a significant advancement in the evolving treatment landscape for rare blood disorders. By introducing a first-in-class oral pyruvate kinase activator for adults with thalassaemia, the European Commission has opened the door to a potentially transformative new approach to managing this lifelong disease.
As rollout efforts begin across Europe, healthcare providers, patients, and advocacy organisations will be closely watching how the therapy performs in real-world clinical practice. For many adults living with thalassaemia, the availability of a new oral treatment option may represent a meaningful step toward improved disease control, reduced treatment burden, and better long-term quality of life.
About Thalassaemia
Thalassaemia is a rare, inherited blood disease that affects the production of haemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. The disease is categorised into two main types: alpha-thalassaemia and beta-thalassaemia, depending on which globin chain of the haemoglobin is affected. By disrupting haemoglobin production, thalassaemia reduces the number of circulating red blood cells and shortens their lifespan, which leads to anaemia, fatigue, and serious complications.
Some individuals with thalassaemia require regular transfusions (classified as transfusion-dependent thalassaemia), while others only need them intermittently (classified as non-transfusion-dependent thalassaemia). All patients with thalassaemia experience a significant disease burden, including comorbidities, reduced quality of life and shortened life expectancy.
About ENERGIZE and ENERGIZE-T
ENERGIZE (NCT04770753) and ENERGIZE-T (NCT04770779) are global, double-blind, placebo-controlled Phase 3 trials evaluating the efficacy and safety of mitapivat in adults with alpha- or beta-thalassaemia.
The ENERGIZE trial randomised 194 non-transfusion-dependent alpha- or beta-thalassaemia patients 2:1 to receive either mitapivat 100 mg twice daily or placebo. The primary endpoint was haemoglobin response, defined as an increase of ≥1.0 g/dL in average haemoglobin concentration from Week 12 through Week 24 compared with baseline. Key secondary endpoints included changes from baseline in average fatigue scores and in average haemoglobin concentration from Week 12 to Week 24. The trial also assessed safety and tolerability.
The ENERGIZE-T trial randomised 258 transfusion-dependent alpha- or beta-thalassaemia patients 2:1 to receive either mitapivat 100 mg twice daily or placebo. The primary endpoint was transfusion reduction response, defined as a ≥50% reduction in transfused red blood cell (RBC) units with a reduction of ≥2 units of RBCs transfused in any consecutive 12-week period through Week 48 compared with baseline. Several transfusion reduction measures were included as key secondary endpoints, and achievement of transfusion independence was a secondary endpoint. The trial also assessed safety and tolerability.
For each trial, patients who completed the double-blind period had the option to transition into a corresponding open-label extension period, during which all patients received mitapivat.
About Avanzanite Bioscience
Avanzanite is redefining launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the Netherlands, the company partners with biotech innovators to unlock the full commercial value of orphan medicines through a fully integrated platform spanning 32 countries. With our deep expertise in market access, we navigate Europe’s complex landscape like master chess players – ensuring no patient is left behind while delivering measurable impact and growth opportunities for alliance partners.
